Please Wait

Applying Filters...

FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

Data Compilation
#PharmaFlow

Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

Stock Recap
#PipelineProspector

Cisatracurium Besylate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

30 API Suppliers, 13 USDMF, 6 CEP/COS, 1 EU WC, 5 NDC API, 17 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

116 FDF Dossiers, 46 FDA Orange Book, 24 Europe, 2 Canada, 11 South Africa, 33 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 1 Actylis, 2 Finar

EXCIPIENTS BY APPLICATIONS

2 Parenteral, 2 Topical, 1 Solubilizers

DIGITAL CONTENT

28 News #PharmaBuzz

28 News #PharmaBuzz

MARKET PLACE

14 APIs, 10 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 Health Canada Patents

2 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 6 USP, 1 Others

$ Xls

Filters

$NDC 0074-4382-20 \nNimbexÂ® \n(cisatracurium\nbesylate) injection \n200 mg/20 mL* \n(10 mg/mL) \nWARNING: Paralyzing Agent\nSingle-dose vial \nDiscard Unused Portion \nFor ICU use only.\nRx only \nabbvie \n$

INJECTABLE;INJECTION - EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

$NDC 0074-4380-10 \nNimbexÂ® \n(cisatracurium \nbesylate) injection \n20 mg/10 mL* \n(2 mg/mL) \nWARNING: Paralyzing Agent\nMultiple-dose vial \n0.9% benzyl alcohol \n(added as a \npreservative)\nRx only \nabbvie \n$

INJECTABLE;INJECTION - EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

X

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Cisatracurium Besylate

Cisatracurium Besylate

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

30 API Suppliers

13 USDMF

6 CEP/COS

1 EU WC

5 NDC API

17 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

9 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

116 FDF Dossiers

46 FDA Orange Book

24 Europe

2 Canada

11 South Africa

33 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical

1 Actylis

2 Finar

EXCIPIENTS BY APPLICATIONS

2 Parenteral

2 Topical

1 Solubilizers

DIGITAL CONTENT

28 News #PharmaBuzz

MARKET PLACE

14 APIs

10 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM

6 USP

1 Others

Filters

INJECTABLE;INJECTION - EQ 10MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 2MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons